» Articles » PMID: 15109416

Neutralizing Antibodies and Sin Nombre Virus RNA After Recovery from Hantavirus Cardiopulmonary Syndrome

Overview
Date 2004 Apr 28
PMID 15109416
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Patients who later have a mild course of hantavirus cardiopulmonary syndrome (HCPS) are more likely to exhibit a high titer of neutralizing antibodies against Sin Nombre virus (SNV), the etiologic agent of HCPS, at the time of hospital admission. Because administering plasma from patients who have recovered from HCPS to those in the early stages of disease may be an advantageous form of passive immunotherapy, we examined the neutralizing antibody titers of 21 patients who had recovered from SNV infection. Even 1,000 days after admission to the hospital, 6 of 10 patients had titers of 800 or higher, with one sample retaining a titer of 3,200 after more than 1,400 days. None of the convalescent-phase serum samples contained detectable viral RNA. These results confirm that patients retain high titers of neutralizing antibodies long after recovery from SNV infection.

Citing Articles

Presence and Persistence of Andes Virus RNA in Human Semen.

Zust R, Ackermann-Gaumann R, Liechti N, Siegrist D, Ryter S, Portmann J Viruses. 2023; 15(11).

PMID: 38005942 PMC: 10675069. DOI: 10.3390/v15112266.


Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein.

Rissanen I, Stass R, Krumm S, Seow J, Hulswit R, Paesen G Elife. 2020; 9.

PMID: 33349334 PMC: 7755396. DOI: 10.7554/eLife.58242.


Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo.

Garrido J, Prescott J, Calvo M, Bravo F, Alvarez R, Salas A Sci Transl Med. 2018; 10(468).

PMID: 30463919 PMC: 11073648. DOI: 10.1126/scitranslmed.aat6420.


Fatal Puumala Hantavirus Disease: Involvement of Complement Activation and Vascular Leakage in the Pathobiology.

Sironen T, Sane J, Lokki M, Meri S, Andersson L, Hautala T Open Forum Infect Dis. 2017; 4(4):ofx229.

PMID: 29255728 PMC: 5726462. DOI: 10.1093/ofid/ofx229.


T-cell epitopes predicted from the Nucleocapsid protein of Sin Nombre virus restricted to 30 HLA alleles common to the North American population.

Sankar S, Ramamurthy M, Nandagopal B, Sridharan G Bioinformation. 2017; 13(3):94-100.

PMID: 28584450 PMC: 5450251. DOI: 10.6026/97320630013094.


References
1.
Terajima M, Hendershot 3rd J, Kariwa H, Koster F, Hjelle B, Goade D . High levels of viremia in patients with the Hantavirus pulmonary syndrome. J Infect Dis. 1999; 180(6):2030-4. DOI: 10.1086/315153. View

2.
Rosenberg R, Waagner D, Romano M, Kanase H, Young R . Hantavirus pulmonary syndrome treated with inhaled nitric oxide. Pediatr Infect Dis J. 1998; 17(8):749-52. DOI: 10.1097/00006454-199808000-00018. View

3.
Botten J, Mirowsky K, Kusewitt D, Bharadwaj M, Yee J, Ricci R . Experimental infection model for Sin Nombre hantavirus in the deer mouse (Peromyscus maniculatus). Proc Natl Acad Sci U S A. 2000; 97(19):10578-83. PMC: 27067. DOI: 10.1073/pnas.180197197. View

4.
Young J, Hansen G, Graves T, Deasy M, Humphreys J, Fritz C . The incubation period of hantavirus pulmonary syndrome. Am J Trop Med Hyg. 2001; 62(6):714-7. DOI: 10.4269/ajtmh.2000.62.714. View

5.
MAIZTEGUI J, Fernandez N, de Damilano A . Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979; 2(8154):1216-7. DOI: 10.1016/s0140-6736(79)92335-3. View